Cargando…

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex

Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in development for the treatment of infections caused by Acinetobacter, including multidrug-resistant (MDR) isolates. Although sulbactam is a β-lactamase inhibitor of a subset of Ambler class A enzymes, it also demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Donnell, John P, Bhavnani, Sujata M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	SUL-DUR Supplement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150273/ https://www.ncbi.nlm.nih.gov/pubmed/37125469 http://dx.doi.org/10.1093/cid/ciad096

Ejemplares similares

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections
por: Watkins, Richard R, et al.
Publicado: (2023)

Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species
por: Papp-Wallace, Krisztina M, et al.
Publicado: (2023)

Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex
por: Castanheira, Mariana, et al.
Publicado: (2023)

Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
por: Shields, Ryan K, et al.
Publicado: (2023)

Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial
por: Watkins, Richard R, et al.
Publicado: (2023)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

1254. In vitro activity of sulbactam-durlobactam against recent global clinical Acinetobacter baumannii-calcoaceticus complex isolates
por: McLeod, Sarah, et al.
Publicado: (2020)

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021
por: Karlowsky, James A., et al.
Publicado: (2022)

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review
por: Principe, Luigi, et al.
Publicado: (2022)

2517. Activity of Sulbactam-durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates
por: Huband, Michael D, et al.
Publicado: (2023)

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii
por: Moussa, Samir H., et al.
Publicado: (2023)

In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam
por: VanNatta, Mollie, et al.
Publicado: (2023)

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function
por: Larson, Kajal, et al.
Publicado: (2023)

85. Efficacy of Sulbactam-Durlobactam (SUL-DUR) Compared to Colistin (COL) against Acinetobacter baumannii-calcoaceticus Complex (ABC) Monomicrobial and Polymicrobial Infections in a Phase 3 Trial
por: Miller, Alita, et al.
Publicado: (2023)

Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex
por: Ye, Jung-Jr, et al.
Publicado: (2016)

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
por: O’Donnell, John, et al.
Publicado: (2019)

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece
por: Petropoulou, Dimitra, et al.
Publicado: (2022)

1293. Sulbactam-durlobactam is active against recent, multi-drug resistant Acinetobacter baumannii clinical isolates from the Middle East
por: Miller, Alita, et al.
Publicado: (2020)

In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy
por: Segatore, Bernardetta, et al.
Publicado: (2022)

709. In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam–Durlobactam (ETX2514SUL) Against Pathogenic Burkholderia Species
por: O’Donnell, John, et al.
Publicado: (2019)

Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including Acinetobacter baumannii
por: Onita, Tetsushu, et al.
Publicado: (2023)

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
por: Shapiro, Adam B., et al.
Publicado: (2021)

694. In vitro Antibacterial Activity of Sulbactam–Durlobactam (ETX2514SUL) Against 121 Recent Acinetobacter baumannii Isolated from Patients in India
por: Miller, Alita, et al.
Publicado: (2019)

Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization
por: Tiseo, Giusy, et al.
Publicado: (2023)

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
por: Sagan, Olexiy, et al.
Publicado: (2020)

Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016)
por: Gales, Ana C, et al.
Publicado: (2019)

Advances in automated techniques to identify Acinetobacter calcoaceticus–Acinetobacter baumannii complex
por: Bagudo, Ahmad Ibrahim, et al.
Publicado: (2020)

Dynamics of a Sporadic Nosocomial Acinetobacter calcoaceticus – Acinetobacter baumannii Complex Population
por: Villalón, Pilar, et al.
Publicado: (2019)

Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review
por: Granata, Guido, et al.
Publicado: (2022)

In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales
por: Fouad, Aliaa, et al.
Publicado: (2023)

Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii
por: Kuo, Shu-Chen, et al.
Publicado: (2015)

Endemicity of Acinetobacter calcoaceticus-baumannii Complex in an Intensive Care Unit in Malaysia
por: Dhanoa, Amreeta, et al.
Publicado: (2015)

2121. In vitro Synergy of the Combination of Sulbactam-Durlobactam and Cefepime at Clinically Relevant Concentrations Against A. baumannii, P. aeruginosa, and Enterobacterales
por: Fouad, Aliaa, et al.
Publicado: (2023)

Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii
por: Temocin, Fatih, et al.
Publicado: (2015)

A Microbiological Study of Acinetobacter calcoaceticus baumannii with Special Reference to Multidrug Resistance
por: Longjam, Langamba Angom, et al.
Publicado: (2021)

Comparison of clinical manifestations and antibiotic resistances among three genospecies of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex
por: Chen, Lu, et al.
Publicado: (2018)

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii
por: Zhang, Jiayuan, et al.
Publicado: (2022)

Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii
por: Zhu, Shixing, et al.
Publicado: (2022)

Risk factors and clinical responses of pneumonia patients with colistin-resistant Acinetobacter baumannii-calcoaceticus
por: Aydemir, Hande, et al.
Publicado: (2019)

2526. Ex Vivo Assessment of Sulbactam-Durlobactam (SUL-DUR) Clearance during Continuous Renal Replacement Therapy (CRRT)
por: Abouelhassan, Yasmeen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5pajui4dm4u0sl6dph88d8ho1b